Tilray, a Nanaimo-based company with a controversial reputation as an opponent of Canada’s craft cannabis industry, is teaming up with Alef Biotechnology SpA on the export deal, according to a news release.
Tilray estimates the potential patient base in Chile is roughly 88,000. Products will be distributed via pharmacies and hospitals in Santiago, Chile’s capital city.
The announcement yesterday “marks Tilray’s entrance into Latin America and expands our international reach to a fourth continent,” said president and CEO Brendan Kennedy. Tilray products are also currently available in Australia and Europe.
Meanwhile, Alef has secured exclusive rights to distribute the LP’s products in Brazil, which is part of Tilray’s plan to continue expanding on a global scale.